MedWatch

Demant rejects criticisms of lobbying efforts against OTC channel: "That’s how America works"

To ensure users receive a high-quality device, CEO Søren Nielsen says Demant has lobbied the FDA through a US-based industry association as it attempts to established the rules for the upcoming over-the-counter hearing aids sales channel.

Søren Nielsen, CEO of Demant | Photo: Demant / PR

One of the world’s leading companies within the hearing aid sector, Danish company Demant, has been a part of trying to influence the US authorities’ implementation of the upcoming over-the-counter (OTC) hearing aids sales channel in the country.

The overall effort is led by industry organization Hearing Industries Association (HIA), of which Demant subsidiary Oticon is a member. HIA has utilized special advisors in connection with a public hearing initiated by the US Food and Drug Administration (FDA).

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

FDA fast-tracks Eli Lilly's obesity candidate

Tirzepatide is already approved for type 2 diabetes, and Lilly has been vying for access to the obesity market for a while – the day the drug could be approved in both indications has now been moved up.

Jefferies spots weaknesses in GN

One potential chink in GN’s armor is that the company’s newly announced hearing aid platform, Omnia, isn’t predicted to win significant market shares.

Further reading

Related articles

Latest news

See all jobs